{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG000","lowerLimit":"12.89","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG001","lowerLimit":"8.42","upperLimit":"NA","value":"NA"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG002","lowerLimit":"1.68","upperLimit":"NA","value":"21.47"},{"comment":"Could not be estimated due to the insufficient number of events.","groupId":"OG003","lowerLimit":"1.64","upperLimit":"NA","value":"6.21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Time to AML progression was defined as the time from the date of first dose of IP until the date the participant had documented progression to AML.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were given oral azacitidine (AZA) 100 mg, 150 mg, or 200 mg tablets twice daily (BID) on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG000","title":"Stable Disease (SD) Cohort: Oral Azacitidine"},{"description":"Participants were given oral azacitidine 100 mg, 150mg, or 200mg tablets BID on days 1 to 21 of each 28-day treatment cycle. Participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG001","title":"Progressive Disease (PD) Cohort: Oral Azacitidine"},{"description":"Participants received 100 mg oral azacitidine (AZA) tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab (Durva) 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG002","title":"Stable Disease Cohort: Oral Azacitidine and Durvalumab"},{"description":"Participants received 100 mg oral azacitidine tablets BID on days 1 to 14 or days 1 to 21 of each 28-day treatment cycle and durvalumab 1500 mg by intravenous infusion on day 1 of each 28-day treatment cycle; participants continued to receive their assigned study treatment unless disease progression, unacceptable toxicity, lost to follow-up or withdrawal by participant occurred.","id":"OG003","title":"Progressive Disease Cohort: Oral Azacitidine and Durvalumab"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all enrolled participants who received at least one dose of investigational product (IP).","reportingStatus":"POSTED","timeFrame":"From first dose and until death, loss to follow-up, withdrawal of consent for further data collection (Up to 91 months)","title":"Kaplan-Meier Estimate of Time to Progression to AML","type":"SECONDARY","unitOfMeasure":"Months"}